Harrow Health (HROW) Earnings Dates, Call Summary & Reports

Q: When does Harrow Health Inc (HROW) report earnings?

Harrow Health Inc (HROW) is schdueled to report earning on May 07, 2026, After Close (Confirmed).

Q: What is Harrow Health Inc (HROW) earnings time?

Harrow Health Inc (HROW) earnings time is at May 07, 2026, After Close (Confirmed).

Q: Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

Q: What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

Q: What is HROW EPS forecast?

HROW EPS forecast for the fiscal quarter 2026 (Q1) is -0.22.

Compare

587 Followers

Earnings Data

Report Date

May 07, 2026

After Close (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

-0.22

Last Year’s EPS

-0.5

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 8 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Mar 02, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call conveyed a broadly positive outlook: strong 2025 financial performance with double‑digit revenue growth, significant adjusted EBITDA expansion, healthy cash generation, multiple product-specific accelerations (BYOOVIZ, IHEEZO, TRIESENCE, VEVYE), concrete 2026 guidance with clear second‑half weighting, and promising pipeline milestones (G-MELT NDA target, IHEEZO data flow). Near‑term headwinds — Q1 seasonality/channel drawdown, ASC pass‑through loss for IHEEZO, compounding inventory issues, and planned SG&A/R&D investments — are acknowledged and largely presented as manageable or temporary in nature. Given the weight and scale of the positive operating and financial indicators relative to the near-term, addressable challenges, the overall tone is constructive and growth‑oriented.

Company Guidance

Harrow guided to full‑year 2026 revenue of $350–$365 million (H1 $133–$153M; H2 $203–$226M) and adjusted EBITDA of $80–$100 million (majority weighted to H2), with SG&A rising to ~$185–$205M and R&D ~$30–$35M as the company adds roughly 100 sales roles in H1 and doubles the VEVYE and TRIESENCE sales forces (VEVYE ramp by Memorial Day); management expects Q1 to be the weakest quarter due to channel inventory drawdown, insurance resets and high‑deductible mix, expects compounded revenue of ~$60–$65M in 2026, and signaled key timing: IHEEZO pass‑through loss April 1 (~30% of 2025 units in ASCs) with price improvement and new retina packaging in H2 and ASRS data in July (Harrow’s 240‑patient Phase 4 readout by YE‑2026), G‑MELT NDA targeted in early 2027; 2025 results to benchmark the guide included Q4 revenue $89.1M (+33% YoY), FY revenue $272M (+36% YoY), Q4 adjusted EBITDA $24.2M and FY adjusted EBITDA $61.9M (+54% YoY), ~$44M cash from operations and $72.9M cash on hand, and notable product metrics (BYOOVIZ Q4 $25.9M / FY $88.7M; IHEEZO Q4 $35.9M / FY $81.3M; TRIESENCE Q4 $5.1M / FY $9.9M; rare & compounded Q4 $22.2M / FY $92.3M), plus an $8.5M Q4 acquired/processed R&D charge related to the Melt acquisition.

Strong Revenue Growth

Consolidated Q4 2025 revenue of $89.1M (+33% YoY) and full-year 2025 revenue of $272M (+36% vs 2024), demonstrating robust top-line expansion across the branded portfolio.

Meaningful Profitability and Cash Generation

Adjusted EBITDA of $24.2M in Q4 and $61.9M for the full year (adjusted EBITDA growth +54% YoY) and ~ $44M generated from operations in 2025; year-end cash and cash equivalents $72.9M.

BYOOVIZ Outperformance

BYOOVIZ Q4 revenue $25.9M (+14% sequentially) and full-year revenue $88.7M (+216% vs 2024), reflecting strong adoption and expanding demand for the Lucentis-referenced biosimilar.

Accelerating IHEEZO Momentum

IHEEZO Q4 revenue $35.9M and full-year $81.3M; reported 64% quarter-over-quarter growth and 65% year-over-year growth in unit demand; retina now ~70% of Q4 unit volume and ordering accounts up 49% YoY; pricing improvement expected in H2 2026 and dedicated retina packaging being launched.

Rapid TRIESENCE Adoption

TRIESENCE Q4 revenue $5.1M (Q4 vs Q3 +36%) and full-year $9.9M (+193% vs 2024); company is doubling the dedicated TRIESENCE sales force to deepen penetration in ocular inflammation and surgery markets; Phase 3/IND progress announced for cataract label expansion.

VEVYE Commercial Inflection

VEVYE prescribers writing VEVYE increased by 115%; covered patients average ~9 refills annually (persistence ~1 year); expanded payer coverage effective Jan 1, 2026 and plan to more than double the VEVYE sales force to capture multi‑hundred‑million-dollar potential (company expects VEVYE to become a 9‑figure product).

2026 Guidance and Upside Pathway

Company guides 2026 revenue $350M–$365M with adjusted EBITDA $80M–$100M, with explicit H1 revenue guide $133M–$153M and H2 $203M–$226M showing expected second-half acceleration from launches, salesforce expansion, and pricing tailwinds.

Pipeline and M&A Synergies (Melt Acquisition)

Melt acquisition programs (G-MELT and YOCHIL) prioritized: G-MELT on track for NDA submission in early 2027 with potential to be a large, opioid-free procedural sedation product; multiple IHEEZO clinical readouts planned (investigator-initiated data at ASRS July 2026 and company Phase 4 readout end of 2026) to support broader adoption.

Operational Investments to Support Scale

Plan to add ~100 sales roles in H1 2026 and double salesforces behind VEVYE and TRIESENCE; SG&A being increased to support launches (VEVYE, TRIESENCE, BYOOVIZ, BYQLOVI) while maintaining focus on profitability and cash generation.

Harrow Health (HROW) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HROW Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 07, 2026	2026 (Q1)	-0.22 / -	-0.5	―	―	―
Mar 02, 2026	2025 (Q4)	0.37 / 0.17	0.24	-29.17% (-0.07)
Nov 10, 2025	2025 (Q3)	0.21 / 0.03	-0.12	125.00% (+0.15)
Aug 11, 2025	2025 (Q2)	<0.01 / 0.13	-0.18	172.22% (+0.31)
May 08, 2025	2025 (Q1)	-0.05 / -0.50	-0.38	-31.58% (-0.12)
Mar 27, 2025	2024 (Q4)	0.08 / 0.24	-0.26	192.31% (+0.50)
Nov 13, 2024	2024 (Q3)	-0.05 / -0.12	-0.13	7.69% (+0.01)
Aug 07, 2024	2024 (Q2)	-0.18 / -0.18	-0.14	-28.57% (-0.04)
May 13, 2024	2024 (Q1)	-0.22 / -0.38	-0.22	-72.73% (-0.16)
Mar 19, 2024	2023 (Q4)	-0.04 / -0.26	0.04	-750.00% (-0.30)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HROW Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Mar 02, 2026	$53.59	$38.60	-27.96%
Nov 10, 2025	$34.14	$38.74	+13.47%
Aug 11, 2025	$33.74	$34.83	+3.23%
May 08, 2025	$23.59	$24.40	+3.43%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Harrow Health Inc (HROW) report earnings?

Harrow Health Inc (HROW) is schdueled to report earning on May 07, 2026, After Close (Confirmed).

What is Harrow Health Inc (HROW) earnings time?

Harrow Health Inc (HROW) earnings time is at May 07, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is HROW EPS forecast?

HROW EPS forecast for the fiscal quarter 2026 (Q1) is -0.22.

Harrow Health (HROW) Earnings News

Harrow Health (NASDAQ:HROW) Plummets on Dismal Q3 Print

Premium

Market News

Harrow Health (NASDAQ:HROW) Plummets on Dismal Q3 Print

2y ago

HROW

See More HROW News >